Stocksigma LogoStocksigma Logo

Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

■ Revenue: 1,943 (+10.3% YoY | +18.5% QoQ) ■ EBITDA: 96.4 (+11.8% YoY | +79.5% QoQ) ■ EBITDA Margin (%): 5.0 (+7 bps YoY | +168 bps QoQ) ■ PAT: 78.5

Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

Sandu Pharmaceuticals Ltd · Outcome · 15 Nov 2026, 12:22 am

Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 1,943 (+10.3% YoY | +18.5% QoQ) ■ EBITDA: 96.4 (+11.8% YoY | +79.5% QoQ) ■ EBITDA Margin (%): 5.0 (+7 bps YoY | +168 bps QoQ) ■ PAT: 78.5 (+49.8% YoY | +244.1% QoQ) ■ EPS (INR): 0.81 (+50.0% YoY | +118.9% QoQ)

Original exchange filing (PDF)

More announcements from Sandu Pharmaceuticals Ltd

All Sandu Pharmaceuticals Ltd announcements